Kinled is a company which retains the assets of the Anglo-Austrian Aisher Family through direct investments in innovative businesses in the Life Science and Digital Technology sectors.
To learn more about our history, Click Here
Today, in life sciences, we have a laser-focus on innovation in the biomedical technology, medical devices, bio pharmaceuticals, and healthcare services sectors, which represents over 50% of our portfolio.
In digital technologies, we invest in SaaS-enabled networks and marketplaces, where technology can democratize markets and provide consumers with greater choice of services.
In fintech, we invest in companies that use technology to challenge the traditional established institutions by providing superior service in embedded payment platforms, insurance, real estate, lending and banking.
Kinled Holding is a Partner in four dedicated life science investment companies based in Boston, Vienna, Monte Carlo, and Zurich, with combined Assets under Management of $250M, and two specific digital technology Funds based in Vienna and London with combined Assets under Management of €225M.
Kinled Holding and the Aisher Family have long believed in fostering academic projects to become commercial businesses.
We have proudly funded early stage businesses in Austria and Switzerland that originated in Universities such as Zürich, Bern, Fribourg, Geneva, Lausanne, Graz, Innsbruck, and Vienna and have a substantial track record of developing successful international businesses from within with the Swiss Federal Institute of Technology and the University of Vienna.
In the United States, we funded early stage businesses that originated in Universities from Boston, Cambridge, Harvard, Houston, Massachusetts Institute of Technology, Michigan, New York, Northeastern, San Diego, San Francisco, to Stanford. In Europe Kinled portfolio firms were created with technology from Universities such as Aix-Marseille, Amsterdam, Barcelona, Helsinki, Linköping, London, Paris, Pecs, and Utrecht.
To learn more about some of successful exits, Click Here >
Kinled has created a number of mechanisms to allow co-investment from sophisticated and qualified family-offices who wish to support us in developing academic/scientific projects and nascent technologies.
Today all our investments are processed through three independently-managed incubator/accelerators that Kinled is a founder shareholder in, and one EU regulated fund, and one unregulated investment company, that we manage:
Cebina The Central European Biotech Incubator & Accelerator at the University of Vienna’s Campus Biotech, supports innovative biotechnology companies focused on inflammation, neurology and ageing.
Mountain Labs is Switzerland’s first full service search lab, start-up incubator and technology investment facilitator, sourcing new investment opportunities and bridging the gap between entrepreneurs and capital finance.
Cebina Bridge Capital is an EU AIFMD regulated fund whose objective is to provide absolute return to Participating Shareholders by investing in pharmaceutical drug discovery and biotech projects in Central and Eastern Europe.
Danube Labs brings together CEBINA’s strength in scientific innovation and entrepreneurship, with Evotec’s industry-leading drug discovery and development expertise to accelerate academic life science research projects with a focus on Central and Eastern European Universities and Research Institutes.
Opportunistic Limited Partners, a professionally managed unregulated private investment company, administered by Landmark Management SAM in Monte Carlo, seeking to produce long-term returns through later-stage/pre-IPO life science opportunities, balanced by a conservative portfolio of residential real estate and public equities.